Skyrizi® Pre-fill Cartridge with Injector for Crohn's and Ulcerative Colitis

What Skyrizi® Is and How It Works

Skyrizi® (risankizumab) is a monoclonal antibody that targets interleukin‑23 (IL‑23). It helps reduce gut inflammation in adults with Crohn’s disease and ulcerative colitis. This page covers the Skyrizi Pre-fill Cartridge w/ Injector used for maintenance dosing. Many patients search for Skyrizi Pre-fill Cartridge w/ Injector without insurance to manage costs. YouDrugstore is a licensed Canadian pharmacy in Manitoba, and our pharmacists review each prescription before dispensing. We work with licensed, vetted partner pharmacies to supply authentic brand medicines at fair prices and a broad selection.

The pre-fill cartridge delivers 360 mg subcutaneously with an on-body injector after intravenous induction. For Crohn’s disease and ulcerative colitis, induction is given by IV at weeks 0, 4, and 8. The first on-body injection is at week 12, then every 8 weeks. The device adheres to the skin and administers the dose over several minutes. Other Skyrizi forms exist for plaque psoriasis and psoriatic arthritis, but this item is the cartridge with on-body injector for inflammatory bowel disease maintenance.

You can order online or by phone. Our customer-service chat is available during posted office hours if you have ordering questions. We ship to the US with prompt, express, cold-chain shipping to protect temperature-sensitive products.

Dosage and Usage

For adults with Crohn’s disease or ulcerative colitis, maintenance dosing after IV induction is 360 mg subcutaneously at week 12 and every 8 weeks. The pre-fill cartridge is loaded into the on-body injector and applied to the abdomen or thigh as instructed by a healthcare professional.

• Allow the carton to reach room temperature on a clean surface before use. A warming time of about 45 minutes is typical.
• Visually inspect the cartridge; the liquid should be clear to slightly yellow and free of particles.
• Load the cartridge into the injector per the device instructions, then apply to intact skin.
• Start the injection. The device delivers the full dose over several minutes. Keep the injector in place until the indicator confirms completion.
• Dispose of the used cartridge and device in a sharps container.

If a maintenance dose is missed, administer it as soon as possible and then continue on the 8‑week interval from the new date, unless the prescriber advises otherwise. Do not use if the solution is discolored, frozen, or has been mishandled.

• Storage: Store in a refrigerator at 2–8 °C (36–46 °F). Keep in the original carton to protect from light. Do not freeze or shake.
• Room-temperature allowance: If needed, keep at room temperature up to 25 °C (77 °F) for up to 30 days. Do not return to the refrigerator once stored at room temperature.
• Travel: Use an insulated cooler with ice packs to keep 2–8 °C. Keep the device dry and protected. Do not leave in a hot car or near heat sources.
• Before use: You can remove a dose from the fridge about 45 minutes before application to reduce discomfort.

Benefits and Savings

Skyrizi® helps reduce flares, diarrhea, and abdominal pain in Crohn’s disease and ulcerative colitis. Many patients reach clinical remission and improve endoscopic findings. Dosing is every 8 weeks after induction, which supports home use and fewer treatment days.

Ordering through a licensed Canadian pharmacy can lower out‑of‑pocket costs. Typical savings are 60–80% compared with common US prices. Patients paying without insurance often choose multi‑month supplies to decrease per‑month costs and reduce shipping fees.

Side Effects and Safety

Most people tolerate therapy well, but side effects can occur. This is not a complete list.

• Common: upper respiratory infections, headache, fatigue, injection-site redness or pain, nausea, rash, pruritus.
• Less common: dizziness, abdominal pain, back pain, elevated liver enzymes.
• Serious: serious infections (including tuberculosis), hypersensitivity reactions, anaphylaxis. Seek urgent care for hives, trouble breathing, chest tightness, or severe swelling.

Screen for tuberculosis before starting. Avoid live vaccines during treatment. Tell the prescriber about current infections, chronic conditions, recent vaccines, and all medicines, including biologics and immunosuppressants.

Onset Time

After IV induction, many patients notice improved symptoms by the maintenance start around week 12. With the on-body injector schedule, additional gains may appear over the next several weeks. Individual response varies by disease severity, prior biologic exposure, and adherence.

Compare With Alternatives

Humira® (adalimumab) is a TNF inhibitor used for Crohn’s disease and ulcerative colitis. It is given subcutaneously, often every 2 weeks after a loading phase. It can also treat plaque psoriasis and psoriatic arthritis. Some patients prefer Skyrizi® due to the 8‑week maintenance interval.

Stelara® Prefilled Syring (ustekinumab) blocks IL‑12/23. It starts with an IV induction dose, then subcutaneous injections every 8 or 12 weeks. It is approved for Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Choice depends on prior biologics, comorbidities, and prescriber guidance.

Enbrel® Pre Filled Syringe (etanercept) is a TNF inhibitor used for plaque psoriasis and psoriatic arthritis. It is not indicated for inflammatory bowel disease. It may be considered for patients focused on skin and joint control rather than gut disease.

Combination Therapy

In inflammatory bowel disease, risankizumab may be used with aminosalicylates and corticosteroids. Clinicians may taper steroids after response. It can also be used with some immunomodulators. Combining with other biologics or JAK inhibitors is not recommended. Coordinate vaccine plans, and avoid live vaccines during treatment.

Patient Suitability and Cost-Saving Tips

This therapy may not suit patients with active serious infections, uncontrolled chronic infections, or a history of severe hypersensitivity to risankizumab. Screening for tuberculosis is recommended before the first dose. Discuss pregnancy, breastfeeding, cancer history, and recurrent infections with the prescriber.

To manage costs, consider a multi‑month supply when appropriate, as it can lower the per‑month price. Turn on reorder reminders so you do not miss scheduled doses. For current offers and bulk options, see our Skyrizi Pre-fill Cartridge w/ Injector coupon page. Patients seeking Skyrizi Pre-fill Cartridge w/ Injector without insurance can still access Canadian pricing at YouDrugstore. We carry brand and select generics at Canadian prices and provide caring support. For background reading, see our condition pages for Crohns Disease, Plaque Psoriasis, and Psoriatic Arthritis. You can also explore articles such as The Abdomen Part Iii The Right Lower Quadrant and Psoriasis Action Month 2025 Advocating For Support And Solutions.

Authoritative Sources

AbbVie Skyrizi consumer site: indications and safety

Health Canada Drug Product Database: Skyrizi product information

FDA Prescribing Information for Skyrizi (risankizumab)

YouDrugstore provides a simple way to order this temperature‑sensitive medication with pharmacist oversight. Our team supports US delivery with prompt, express, cold-chain shipping so the product stays within the recommended range from our door to yours.

This content is for general information. It does not replace the advice of your healthcare professional. Always follow the dosing and monitoring plan set by your prescriber and the instructions supplied with your device.